Amplia signs Collaboration and Supply Agreement with Lilly
Open PDF
| Stock | Amplia Therapeutics Ltd (ATX.ASX) |
|---|---|
| Release Time | 4 Aug 2026, 8:22 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Amplia Therapeutics signs collaboration with Lilly for NSCLC treatment
Key Points
- Amplia collaborates with Lilly to evaluate narmafotinib and olomorasib combination
- Study targets advanced NSCLC, expanding narmafotinib's clinical development
- Lilly to supply olomorasib, enhancing Amplia's clinical strategy
Full Summary
Amplia Therapeutics Limited has entered into a Clinical Trial Collaboration and Supply Agreement with Eli Lilly & Company to evaluate the combination of Amplia's investigational FAK inhibitor narmafotinib and Lilly's KRAS G12C inhibitor olomorasib as a second-line treatment for advanced non-small cell lung cancer (NSCLC). The Phase 1b/2b clinical trial, planned to begin in late 2026, will be conducted at sites in Australia and the USA. The collaboration aims to address the resistance mechanisms to KRAS G12C inhibitors and leverage narmafotinib's role in suppressing resistance via FAK inhibition. The NSCLC market is currently valued at approximately US$31 billion and is expected to grow to over US$60 billion by 2033.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In